Sale!

Everolimus BSA Conjugate Solution

$695.00 $475.00

Catalog #: P2010024 (0.5 mg)
Concentrated solution of Bovine Serum Albumin (BSA) conjugated to Everolimus. A carbon spacer arm of 19.0 Å links BSA to the Everolimus moiety. Each BSA molecule contains several Everolimus units. Dilutions of the provided conjugate can be made in 1X Phosphate Buffer Saline, pH 7.4.

Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST)

In stock

SKU: P2010024 Categories: ,

Description

Everolimus BSA Conjugate

Product Data Sheet Download PDF
MSDS Download PDF
Catalog number: P2010024
Lot number: 0120P0024
Expiration date: 2024-02
Purity: > 95%
Concentration: 1 mg/mL
Package Size: 0.5 mg
Molecular Weight: 71 kDa (average)
Storage: -20°C. Avoid repeated freeze/thaw cycles.
Other names: BSA-Everolimus, Everolimus-BSA, BSA conjugated to Everolimus, 40-O-(2-hydroxyethyl)-sirolimus BSA, Everolimus Bovine Serum Albumin Conjugate, Everolimus [BSA].
Keywords: BSA conjugate, Everolimus, Certican, Zortress, Afinitor, Votubia, Evertor.
Buffer: 1X Phosphate Buffer Saline, pH 7.4.

About Everolimus

Everolimus is a synthetic derivative of the natural compound sirolimus (40-O-(2-hydroxyethyl)-sirolimus). Everolimus has both immunosuppressant and anti-angiogenic properties. As a result, this molecule finds several applications in organ transplant as well as chemotherapy. Inside the cell, Everolimus inhibits the activation of the mammalian target of Rapamycin (sirolimus) (mTOR).

References

  • Montero N, Pascual J. Immunosuppression and Post-transplant Hyperglycemia. Curr Diabetes Rev. 2015;11(3):144-54.
  • Everolimus. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-2018 Feb 26.
  • Guan TW, Lin YJ, Ou MY, Chen KB. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. Eur J Clin Invest. 2019 Dec;49(12):e13179.
  • Hasskarl J. Everolimus. Recent Results Cancer Res. 2018;211:101-123.
  • Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015 Oct;20(10):1243-9.
  • Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res. 2020 Apr 6;22(1):33.
  • Sammons S, Sedrak MS and Kimmick GG. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. Drugs Aging. 2020 Feb 26.

Related Products

 

Ordering Information

1- Order online using our website’s automated shopping cart and checkout system (available 24/7).

2- Order by email: info@moleculardepot.com (we accept electronic PO, available 24/7).

3- Order by Fax: 1-858-437-9884 (available 24/7).

4- Order by phone: 1-858-900-3210 (6 am – 8 pm PST).

5- Order by Text/SMS: 1-858-900-3210 (6 am – 8 pm PST).